Jena, Germany (ots) - The SIRS-Lab GmbH is focused on the
development of biochips as new diagnostic tools for acute
inflammatory disorders i.e. sepsis. For that purpose SIRS-Lab decided
to acquire prominent assistance. The US-based Public Health Research
Institute (PHRI), Newark, New Jersey, authorizes SIRS-Lab to sell the
Molecular Beacon technology for the European R&D market in the field
of sepsis. The contract is valid for 5 years. With this agreement
SIRS-Lab joins a group of considerable companies world-wide, which
develop and use the Molecular Beacon technology.
Molecular Beacons are small molecules of single-stranded DNA. They
possess a hairpin-shaped structure. At one of their ends they have
bound a fluorophore, at the other a fluorescence quencher. Due to
their conformation, the fluorophore and the quencher are in close
proximity. That causes complete fluorescence quenching. Hybridization
to target DNA opens the hairpin of the probe molecules and separates
fluorophore and quencher. As a result the fluorescence is turned
"on".
"The license agreement with the PHRI opens up new possibilities
for the development of our biochips", said SIRS-Lab's Chief Executive
Officer Dr. Stefan Rußwurm. The use of Molecular Beacons on biochips
would provide several advantages compared to current methods. So far,
sample molecules have to be fluorescence labelled before analysis.
"This step would no longer be necessary and the handling of biochip
experiments would be much easier for our customers", said Rußwurm. In
addition, the Molecular Beacon technology requires only smallest
quantities of sample fluids.
During the next year, SIRS-Lab expects to put their first biochips
on the market, which are equipped with the new technology.
Nevertheless, a lot of developmental work is still required. But
SIRS-Lab is well prepared to do it. A research project funded by the
European Union exclusively focus on the establishment of the
Molecular Beacons technology.
ots Original Text Service: SIRS-Lab GmbH
Internet: www.presseportal.de
For further information please contact
Roberto C. Wolfer
SIRS-Lab GmbH, Jena, Germany
Phone: (+) 49 3641 / 508 250
Email: wolfer@sirs-lab.de
Web: www.sirs-lab.de
development of biochips as new diagnostic tools for acute
inflammatory disorders i.e. sepsis. For that purpose SIRS-Lab decided
to acquire prominent assistance. The US-based Public Health Research
Institute (PHRI), Newark, New Jersey, authorizes SIRS-Lab to sell the
Molecular Beacon technology for the European R&D market in the field
of sepsis. The contract is valid for 5 years. With this agreement
SIRS-Lab joins a group of considerable companies world-wide, which
develop and use the Molecular Beacon technology.
Molecular Beacons are small molecules of single-stranded DNA. They
possess a hairpin-shaped structure. At one of their ends they have
bound a fluorophore, at the other a fluorescence quencher. Due to
their conformation, the fluorophore and the quencher are in close
proximity. That causes complete fluorescence quenching. Hybridization
to target DNA opens the hairpin of the probe molecules and separates
fluorophore and quencher. As a result the fluorescence is turned
"on".
"The license agreement with the PHRI opens up new possibilities
for the development of our biochips", said SIRS-Lab's Chief Executive
Officer Dr. Stefan Rußwurm. The use of Molecular Beacons on biochips
would provide several advantages compared to current methods. So far,
sample molecules have to be fluorescence labelled before analysis.
"This step would no longer be necessary and the handling of biochip
experiments would be much easier for our customers", said Rußwurm. In
addition, the Molecular Beacon technology requires only smallest
quantities of sample fluids.
During the next year, SIRS-Lab expects to put their first biochips
on the market, which are equipped with the new technology.
Nevertheless, a lot of developmental work is still required. But
SIRS-Lab is well prepared to do it. A research project funded by the
European Union exclusively focus on the establishment of the
Molecular Beacons technology.
ots Original Text Service: SIRS-Lab GmbH
Internet: www.presseportal.de
For further information please contact
Roberto C. Wolfer
SIRS-Lab GmbH, Jena, Germany
Phone: (+) 49 3641 / 508 250
Email: wolfer@sirs-lab.de
Web: www.sirs-lab.de
